These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9793827)

  • 1. Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC.
    Viora M; Di Genova G; Quaranta MG; Boirivant M; Camponeschi B
    J Clin Immunol; 1998 Sep; 18(5):346-54. PubMed ID: 9793827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions.
    Mattioli B; Giordani L; Quaranta MG; Viora M
    Life Sci; 2004 Mar; 74(18):2291-300. PubMed ID: 14987953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
    Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
    Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of interleukin-2 receptor gene activation and protein expression by dideoxynucleoside analogs.
    Viora M; Camponeschi B
    Cell Immunol; 1995 Jul; 163(2):289-95. PubMed ID: 7606800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
    Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
    AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
    Chong KT; Pagano PJ; Hinshaw RR
    Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs.
    Viora M; Di Genova G; Rivabene R; Malorni W; Fattorossi A
    Int J Immunopharmacol; 1997 Jun; 19(6):311-21. PubMed ID: 9467750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
    Spector SA; Ripley D; Hsia K
    Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
    Lucia MB; Cauda R; Landay AL; Malorni W; Donelli G; Ortona L
    AIDS Res Hum Retroviruses; 1995 Aug; 11(8):893-901. PubMed ID: 7492436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
    Qian MX; Swagler AR; Mehta M; Vishwanathan CT; Gallo JM
    Pharm Res; 1992 Feb; 9(2):224-7. PubMed ID: 1313173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy.
    Andreoni M; Sarmati L; Nicastri E; Ventura L; Ercoli L; Parisi SG; Giannini G; Galluzzo C; Vella S
    J Med Virol; 1998 Dec; 56(4):332-6. PubMed ID: 9829638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
    Richman DD; Meng TC; Spector SA; Fischl MA; Resnick L; Lai S
    J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):135-8. PubMed ID: 7905522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice.
    Hostetler KY; Richman DD; Sridhar CN; Felgner PL; Felgner J; Ricci J; Gardner MF; Selleseth DW; Ellis MN
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2792-7. PubMed ID: 7695264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
    Benbrik E; Chariot P; Bonavaud S; Ammi-Saïd M; Frisdal E; Rey C; Gherardi R; Barlovatz-Meimon G
    J Neurol Sci; 1997 Jul; 149(1):19-25. PubMed ID: 9168161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.
    Veal GJ; Wild MJ; Barry MG; Back DJ
    Br J Clin Pharmacol; 1994 Oct; 38(4):323-8. PubMed ID: 7833221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
    Watanabe KA; Harada K; Zeidler J; Matulic-Adamic J; Takahashi K; Ren WY; Cheng LC; Fox JJ; Chou TC; Zhu QY
    J Med Chem; 1990 Aug; 33(8):2145-50. PubMed ID: 1695683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
    Connell EV; Hsu MC; Richman DD
    Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
    Perno CF; Yarchoan R; Cooney DA; Hartman NR; Gartner S; Popovic M; Hao Z; Gerrard TL; Wilson YA; Johns DG
    J Exp Med; 1988 Sep; 168(3):1111-25. PubMed ID: 2844951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.